The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality

References

[1] WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976. Acta Obstet Gynecol Scand. 1977;56:247–53.10.3109/00016347709162009Search in Google Scholar

[2] Steer P. The epidemiology of preterm labour. Br J Obset Gynaecol. 2005;112(Suppl 1):1–3.10.1111/j.1471-0528.2005.00575.xSearch in Google Scholar

[3] Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151–61.10.1016/S0140-6736(12)60560-1Search in Google Scholar

[4] Arpino C, Compagnone E, Montanaro ML, Cacciatore D, De Luca A, Cerulli A, et al. Preterm birth and neurodevelopmental outcome: a review. Childs Nerv Syst. 2010;26:1139–49.10.1007/s00381-010-1125-ySearch in Google Scholar PubMed

[5] Iams JD. Clinical practice. Prevention of preterm parturition. N Engl J Med. 2014;370:254–61.10.1056/NEJMcp1103640Search in Google Scholar PubMed

[6] Iams JD. Identification of candidates for progesterone: why, who, how, and when? Obstet Gynecol. 2014;123:1317–26.10.1097/AOG.0000000000000276Search in Google Scholar PubMed

[7] Ruddock NK, Shi SQ, Jain S, Moore G, Hankins GD, Romero R, et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol. 2008;199:391.e1–7.10.1016/j.ajog.2008.06.085Search in Google Scholar PubMed

[8] Administration FaD. 17α-Alpha hydroxyprogesteronecaproate for prevention of pretermbirth: overview of FDA background document. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf2007.Search in Google Scholar

[9] Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379–85.10.1056/NEJMoa035140Search in Google Scholar PubMed

[10] Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357:454–61.10.1056/NEJMoa070641Search in Google Scholar PubMed

[11] Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206:124.e1–19.10.1016/j.ajog.2011.12.003Search in Google Scholar PubMed PubMed Central

[12] O’Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:687–96.10.1002/uog.5158Search in Google Scholar PubMed

[13] Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K, Cooper S, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet. 2009;373:2034–40.10.1016/S0140-6736(09)60947-8Search in Google Scholar

[14] Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF, et al. Progesterone does not prevent preterm births in women with twins. South Med J. 2009;102:900–4.10.1097/SMJ.0b013e3181afee12Search in Google Scholar PubMed

[15] Ibrahim M, Ramy A, Ramy M, Younis M. Progesterone supplementation for prevention of preterm labor: a randomized controlled trial. Middle East Fertil Soc J. 2010;15:39–41.10.1016/j.mefs.2010.03.007Search in Google Scholar

[16] Combs CA, Garite T, Maurel K, Das A, Porto M. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2010;203:248.e1–9.10.1016/j.ajog.2010.06.016Search in Google Scholar PubMed

[17] Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18–31.10.1002/uog.9017Search in Google Scholar PubMed PubMed Central

[18] Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011;38:272–80.10.1097/OGX.0b013e3182439e97Search in Google Scholar

[19] Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJ, et al. 17alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol. 2011;118:513–20.10.1097/AOG.0b013e31822ad6aaSearch in Google Scholar PubMed

[20] Combs CA, Garite T, Maurel K, Das A, Porto M. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2011;204:221.e1–8.10.1016/j.ajog.2010.12.042Search in Google Scholar PubMed

[21] Tan PC, King AS, Vallikkannu N, Omar SZ. Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial. Arch Gynecol Obstet. 2012;285:585–90.10.1007/s00404-011-2026-3Search in Google Scholar PubMed

[22] Grobman WA, Thom EA, Spong CY, Iams JD, Saade GR, Mercer BM, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol. 2012;207:390.e1–8.10.1016/j.ajog.2012.09.013Search in Google Scholar PubMed PubMed Central

[23] Serra V, Perales A, Meseguer J, Parrilla JJ, Lara C, Bellver J, et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. Br J Obset Gynaecol. 2013;120:50–7.10.1111/j.1471-0528.2012.03448.xSearch in Google Scholar

[24] Senat MV, Porcher R, Winer N, Vayssiere C, Deruelle P, Capelle M, et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2013;208:194.e1–8.10.1016/j.ajog.2013.01.032Search in Google Scholar

[25] Awwad J, Usta IM, Ghazeeri G, Yacoub N, Succar J, Hayek S, et al. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. Br J Obset Gynaecol. 2015;122:71–9.10.1111/1471-0528.13031Search in Google Scholar

[26] Winer N, Bretelle F, Senat MV, Bohec C, Deruelle P, Perrotin F, et al. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2015;212:485.e1–10.10.1016/j.ajog.2014.10.1097Search in Google Scholar

[27] Brizot ML, Hernandez W, Liao AW, Bittar RE, Francisco RP, Krebs VL, et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2015;213:82.e1–9.10.1016/j.ajog.2015.02.021Search in Google Scholar

[28] El-Refaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet. 2015;293:61–7.10.1007/s00404-015-3767-1Search in Google Scholar

[29] van Os MA, van der Ven AJ, Kleinrouweler CE, Schuit E, Kazemier BM, Verhoeven CJ, et al. Preventing preterm birth with progesterone in women with a short cervical length from a low-risk population: a multicenter double-blind placebo-controlled randomized trial. Am J Perinatol. 2015;32:993–1000.10.1055/s-0035-1547327Search in Google Scholar

[30] Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 1985;151:574–7.10.1016/0002-9378(85)90141-3Search in Google Scholar

[31] Wood S, Ross S, Tang S, Miller L, Sauve R, Brant R. Vaginal progesterone to prevent preterm birth in multiple pregnancy: a randomized controlled trial. J Perinat Med. 2012;40:593–9.10.1515/jpm-2012-0057Search in Google Scholar PubMed

[32] Johnson JW, Lee PA, Zachary AS, Calhoun S, Migeon CJ. High-risk prematurity – progestin treatment and steroid studies. Obstet Gynecol. 1979;54:412–8.Search in Google Scholar

[33] Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet. 2011;283:423–9.10.1007/s00404-009-1351-2Search in Google Scholar PubMed

[34] Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462–9.10.1056/NEJMoa067815Search in Google Scholar PubMed

[35] Aboulghar MM, Aboulghar MA, Amin YM, Al-Inany HG, Mansour RT, Serour GI. The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reprod Biomed Online. 2012;25:133–8.10.1016/j.rbmo.2012.03.013Search in Google Scholar PubMed

[36] Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbriere R, et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol. 2012;206:206.e1–9.10.1016/j.ajog.2011.12.026Search in Google Scholar PubMed

[37] Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MM. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynaecol Obstet. 2014;126:60–3.10.1016/j.ijgo.2014.01.019Search in Google Scholar PubMed

[38] Martinez de Tejada B, Karolinski A, Ocampo MC, Laterra C, Hosli I, Fernandez D, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. Br J Obset Gynaecol. 2015;122:80–91.10.1111/1471-0528.13061Search in Google Scholar PubMed

[39] Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet. 2009;104:40–3.10.1016/j.ijgo.2008.08.029Search in Google Scholar PubMed

[40] Caritis SN, Simhan HN, Zhao Y, Rouse DJ, Peaceman AM, Sciscione A, et al. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. Am J Obstet Gynecol. 2012;207:396.e1–8.10.1016/j.ajog.2012.08.001Search in Google Scholar PubMed PubMed Central

[41] Usta IM, Usta J, Nassar AH. 17-hydroxy progesterone caproate for preterm labor prevention: final blood levels. Am J Obstet Gynecol. 2013;208:337.10.1016/j.ajog.2012.12.032Search in Google Scholar PubMed

[42] Chang J, Zhao Y, Zhao W, Venkataramanan R, Caritis SN. Quality assessment of compounded 17-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2014;210:47.e1–7.10.1016/j.ajog.2013.09.039Search in Google Scholar PubMed PubMed Central

[43] Manuck TA, Watkins WS, Moore B, Esplin MS, Varner MW, Jackson GM, et al. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention. Am J Obstet Gynecol. 2014;210:321.e1–21.10.1016/j.ajog.2014.01.013Search in Google Scholar PubMed PubMed Central

[44] Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P. Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod. 2000;15(Suppl 1): 129–48.10.1093/humrep/15.suppl_1.129Search in Google Scholar PubMed

[45] O’Brien JM. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens. Ultrasound Obstet Gynecol. 2013;42: 247–53.10.1002/uog.12456Search in Google Scholar PubMed

[46] Romero R, Stanczyk FZ. Progesterone is not the same as 17alpha-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol. 2013;208:421–6.10.1016/j.ajog.2013.04.027Search in Google Scholar PubMed PubMed Central